

Supplement Figure 1. Real-time quantitative PCR of CMTM family.

Real-time quantitative PCR of CMTM3, CMTM6, CMTM7, CMTM8 and CKLF. N=3. NS: no significance * $p < 0.05$. by the one way ANOVA test.

Supplement Figure 2. Different risk signatures of immune micro-environment in consensus clustering subgroups from training and validation cohorts

(A) Tumor purity in cluster 1 and cluster 2 from training and validation cohorts. (B) ESTIMATE score in cluster 1 and cluster 2 from training and validation cohorts. (C) Stromal score in cluster 1 and cluster 2 from training and validation cohorts. (D) Immune score in cluster 1 and cluster 2 from training and validation cohorts. * $p < 0.001$; by the Wilcox test.**

Supplement Figure 3. Immune cells infiltration in cluster 1 and cluster 2 from CGGA325 database

(A-C) CIBERSORT algorithm shows infiltrated immune cells in cluster 1 and cluster 2 from the TCGA (A), CGGA301 (B) and CGGA325 (C) database. * $p < 0.05$, ** $p < 0.01$, * $p < 0.001$, ns:no significant differences; by the Wilcox test.**

Supplement Figure 4. Enriched pathways between cluster 1 and cluster 2 in CGGA325 database

(A) Enriched pathways between cluster 1 and cluster 2 based on KEGG-based GSEA analysis in the CGGA325 database. (B) Enriched pathways between cluster 1 and cluster 2 based on GO-based GSEA analysis in the CGGA325 database. (C) Enriched pathways between cluster 1 and cluster 2 based on GO-based GSVA analysis in the CGGA325 database.

Supplement Figure 5. Validation cohorts of GSE108474 databases.

(A) The CMTM expression in samples from GSE108474 and their corresponding clinical characteristic. Overall survival analysis based on the cluster model (B) and the scoring model (C).

Supplement Figure 6. The relationship between risk score and clinicopathologic features of LGG from training and validation cohorts

(A) Risk score among different IDH subtypes of LGG from the training and validation cohorts. (B) Risk score in LGG patients with different status of 1p/19q from the training and validation cohorts. (C) Risk score in LGG patients with different grades from the training and validation cohorts. (D) Risk score in LGG patients with different status of IDH from the training and validation cohorts. (E) Risk score in LGG patients with different status of MGMT from the training and validation cohorts. * $p < 0.001$, ns: no significant differences; by the Wilcoxon test.**

Supplement Figure 7. Enriched pathways between low and high risk groups in CGGA325 database







(A) Enriched pathways between low-risk and high-risk groups based on KEGG-based GSEA analysis in the CGGA325 database. (B) Enriched pathways between low-risk and high-risk groups based on GO-based GSEA analysis in the CGGA325 database. (C) Enriched pathways between low-risk and high-risk groups based on KEGG-based GSVA analysis in the CGGA325 database. (D) Enriched pathways between low-risk and high-risk groups based on GO-based GSVA analysis in the CGGA325 database.

	TCGA	CGGA-seq	CGGA-array	GSE108474
The number of samples	508	142	155	168
Grade (Grade II, Grade III)	247, 260	93,49	111, 44	86, 82
Gender (Female, Male)	225, 283	55, 87	63, 92	/
IDH (Mutational, wildtype)	411, 94	104, 38	99, 54	/
1p19q (codel. noncodel)	168. 340	54, 88	14, 23	/
MGMT (Methylated, Unmethylated)	419.89	65, 65	37, 105	/
GlioVis subtype (IDHmut-codel, IDHmut-noncodel, IDHwt)	190, 240, 78	63, 67, 12	50, 96, 9	37, 131, 0


Supplementary Table 1 | Description of samples from TCGA, CGGA-seq, CGGA-array database.

	TCGA				CGGA-seq				CGGA-array				GSE108474			
	Univariate Cox		Multivariate Cox		Univariate Cox		Multivariate Cox		Univariate Cox		Multivariate Cox		Univariate Cox		Multivariate Cox	
	P value	HR	P value	HR	P value	HR	P value	HR	P value	HR	P value	HR	P value	HR	P value	HR
Cluster	<0.001	3.375	0.097	0.623	<0.001	2.978	0.642	0.849	0.332	1.883	0.187	0.285	<0.001	1.879	0.362	1.209
Grade	<0.001	3.368	0.3	1.286	<0.001	3.018	<0.001	2.724	0.14	2.183	0.218	3.072	0.13	1.291	0.535	0.889
IDH	<0.001	6.641	0.048	0.449	<0.001	3.512	0.219	0.559	0.044	2.937	0.231	0.359	/	/	/	/
1p19q	<0.001	2.654	0.646	1.139	<0.001	5.583	<0.001	4.767	0.049	3.589	0.019	5.913	/	/	/	/
MGMT	<0.001	2.654	0.964	1.011	0.128	1.484	0.238	1.394	0.182	2.082	0.677	1.403	/	/	/	/
Score	<0.001	1.007	<0.001	1.009	<0.001	1.004	0.016	1.003	0.001	1.006	0.007	1.007	<0.001	1.003	<0.001	1.003


Supplementary Table 2 | Univariate and multivariate Cox regression analysis in TCGA, CGGA-seq, CGGA-array database and GSE108474.




CGGA325 dataset




B




C




D




A




C




B




A







B



C









A

KEGG-GSEA




B

GO-GSEA



C

KEGG-GSVA



D

GO-GSVA

